课题基金 / 基金详情

SPARC AS A REGULATOR OF VEGF ACTIVITY

SPARC AS A REGULATOR OF VEGF ACTIVITY
SPARC 作为 VEGF 活性的调节剂
批准号:
6388772
负责人:
Rolf A Brekken
金额:
$4.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
未结题
起止时间:
2001-06-01 至

项目摘要

项目成果

Rolf A Brekken的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Angiogenesis, the development of new vasculature from preexisting blood vessels, plays a critical role in many physiological processes and pathological events. An increased understanding of how angiogenesis is regulated in tissues would contribute to a variety of biological and medical areas. The extracellular matrix (ECM) and matricellular proteins found in the ECM function as important regulators of angiogenesis by their interaction with endothelial cells and the angiogenic factors that control blood vessel development. SPARC (secreted protein, acidic and rich in cysteine), a matricellular protein, has recently been shown to interact with and regulate the activity of vascular endothelial growth factor (VEGF), a primary stimulant of angiogenesis in both normal and pathological situations. An understanding of the proteins in the ECM that interact with VEGF and their ability to regulate VEGF activity would contribute to our understanding of VEGF-induced angiogenesis and its role in tissue homeostasis and pathology. In this application I will characterize further the interaction of SPARC and VEGF. The ability of SPARC to block VEGF from activating VEGFR1 an VEGFR2 will be determined and the ability of SPARC to regulate VEGF activities including: migration of endothelial cells, chemotaxis of macrophages, and vascular permeability will be examined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer
  • 批准号:
    10414970
  • 项目类别:
  • 资助金额:
    $46.63万
  • 财政年份:
    2020
  • 负责人:
    Rolf A Brekken
  • 依托单位:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
  • 批准号:
    10524152
  • 项目类别:
  • 资助金额:
    $13.03万
  • 财政年份:
    2020
  • 负责人:
    Rolf A Brekken
  • 依托单位:
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer
  • 批准号:
    10653821
  • 项目类别:
  • 资助金额:
    $46.63万
  • 财政年份:
    2020
  • 负责人:
    Rolf A Brekken
  • 依托单位:
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
  • 批准号:
    10210367
  • 项目类别:
  • 资助金额:
    $35.97万
  • 财政年份:
    2020
  • 负责人:
    Rolf A Brekken
  • 依托单位:
海外基金